To analyze the effectiveness of liposomal doxorubicin combined with Hongdoushan capsule in the treatment of advanced platinum resistant ovarian cancer. Methods:A total of 37 patients with advanced platinum resistant ovarian cancer were divided into combined group (20 cases) and single drug group (17 cases). The combination group was given the treatment of liposomal doxorubicin (30～40 mg/m2 intravenously) and Hongdoushan capsule (0.6 g 3/d), and the single drug group was given the treatment of liposomal doxorubicin alone. The short-term efficacy and toxicity were evaluated. ECG, left ventricular ejection fraction, myocardial enzyme changes were monitored to evaluate cardiac toxicity of liposomal doxorubicin. Results:Efficacy rate was 35% in combined group and 23.53% in single group. There was statistical significance between the two groups (P<0.05). The control rate for disease was higher in combined group than the single group, and there was statistical significance between the two groups (P<0.05). KPS score of the combined treatment group improved significantly better than the control group (65% vs 47.06%). The incidences of nausea, vomiting, diarrhea and skin rash, dysfunction of hepatic function in the combined group were higher than the single drug group, while there were no differences between the two groups (P>0.05). Conclusion:Liposomal doxorubicin combined with Hongdoushan capsules in the treatment of advanced platinum resistant ovarian cancer has better clinical benefits and improvement for the quality of life than the single group. The therapy method is worthy to be popularized.